Global Anti Thrombotics Market Analysis, Trends and Opportunities -2019-2025
Summary -
A new market
study, titled “Global Anti Thrombotics Market Analysis,
Trends and Opportunities -2019-2025” has been featured on WiseGuyReports.
Reasons to Purchase
• Gain a truly global perspective
with the most comprehensive report available on this market covering 50+
geographies.
• Create regional and country
strategies on the basis of local data and analysis.
• Identify growth segments for
investment.
• Outperform competitors using
forecast data and the drivers and trends shaping the market.
• Understand customers based on the
latest market research findings.
• Benchmark performance against key
competitors.
• Utilize the relationships between
key data sets for superior strategizing.
• Suitable for supporting your
internal and external presentations with reliable high quality data and
analysis
• Report will be updated with the
latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest
growing market for the anti thrombotics? How does the market relate to the
overall economy, demography and other similar markets? What forces will shape
the market going forward? The Anti Thrombotics Market Global Report from The
Business Research Company answers all these questions and many more.
The report covers market
characteristics, size and growth, segmentation, regional and country
breakdowns, competitive landscape, market shares, trends and strategies for
this market.
• The Market Characteristics section
of the report defines and explains the market.
• The Market Size section gives the
market size ($b) covering both the historic growth of the market and
forecasting the future. Drivers and restraints looks at the external factors
supporting and controlling the growth of the market.
• Market Segmentations break down
market into sub markets.
• The Regional and Country section
gives an analysis of the market in each geography and the size of the market by
geography and compares their historic and forecast growth. It covers all the
regions, key developed countries and major emerging markets. It draws
comparisons with country populations and economies to understand the importance
of the market by country and how this is changing.
• Competitive Landscape gives a
description of the competitive nature of the market, market shares, and a
description of the leading companies. Key financial deals which have shaped the
market in recent years are identified.
• The Trends and Strategies section
highlights the likely future developments in the market and suggests approaches
companies can take to exploit this.
Scope
Markets Covered: 1) By Application:
Blood Clot Prevention, Hyperlipidemia Treatment, Prophylactic Treatment,
Thromboembolic Disease Treatment, Other Applications 2) By Type: Anticoagulant,
Antiplatelet, Thrombolytic Drugs 3) By Class: Fondaparinux, Heparin, Apixaban,
Debigatran, Rivaroxaban 4) By Route Of Administration: Oral, Parenteral Route
5) By Distribution Channel: Hospital Pharmacies, Online Retailers, General
Pharmacies, Drug Stores
Companies Mentioned: Bayer AG,
Johnson & Johnson, Sanofi, Boehringer Ingelheim Gmbh, Eli Lilly
Countries: Australia, Brazil, China,
France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
Regions: Asia-Pacific, Western
Europe, Eastern Europe, North America, South America, Middle East, Africa
Time Series: Five years historic and
forecast.
Data Segmentations: country and
regional historic and forecast data, market share of competitors, market
segments.
Sourcing and Referencing: Data and
analysis throughout the report is sourced using end notes.
The anti-thrombotic drugs market
consists of sales of anti-thrombotic drugs which are used to prevent and treat
arterial and venous thrombosis and as well reduce the formation of clots. The
anti-thrombotic drugs market is segmented into antiplatelet agents, fibrinolytic
drugs, and anticoagulants.
The global anti thrombotics market
was valued at about $8.8 billion in 2018 and is expected to decline to $7.73
billion at a CAGR of -3.2% through 2022.
In 2018, North America was the
largest region in the anti thrombotics market. The anti thrombotics market in
Asia Pacific is forecasted to register the highest CAGR during 2018-2023.
The rise in the chronic diseases
associated with thrombotic diseases is the driving force for the
anti-thrombotic drugs market. Thrombotic diseases require long term treatment
of antithrombotic drugs. This requirement contribute to the sales of
antithrombotic drugs. For example, almost 900,000 people in USA could be
affected with DVT (Deep Venous Thrombosis). Also, there is a 33% chance that DVT
will come back within 10 years to the same patient.
The increased use of biologics is one
of the reasons for the decline in the growth of anti-thrombotic drugs market.
Biologics are the medicines derived from living organisms such as humans,
animals or microorganisms that may contain protein, sugar, nucleic acids or
combination of these substances. Biologics are not chemically synthesized and
hence, they don't fall under the category of drugs. As the usage of biologic
medicines increases, greater portion of synthetic/chemical drugs business will
be taken over affecting the growth of the anti- thrombotic drug market. For
example, in the year 2017, Aplagon Oy and Cadila collaborated for the
production of anti-thrombotic Biologics. Also, in the year 2018, US FDA
approved ATryn, the first ever animal derived biologic anticoagulant product
manufactured by GTC Bio therapeutics. Before ATryn, the human blood derived
product was the only biologic AT (Anti Thrombin) medicine available in the U.S.
Artificial Intelligence (AI)
partnerships are being discussed by almost over 30 major drug manufacturers
such as AstraZeneca, Astellas, Bayer, GSK, Janssen and Merck, in order to find
and validate new drug targets, monitor adherence, better clinical trial
planning and operations, identification of proteins, pharmacovigilance
(monitoring adverse events), drug repurposing, and prediction of disease. AI
could be very beneficial in disease prediction. For example, Janssen recently
announced an agreement with Winterlight Labs to use Winterlight’s voice
analysis technology to predict on-set of dementia. Another example by UK’s
Francis Crick Institute recently showed that predicting heart disease death by
AI was much precise than the prediction by physicians. Thus, improved usage of
AI may help drug makers largely, thereby, driving the market strongly.
The FDA approvals of various
anti-thrombotic drugs impacts the market positively. FDA approves a few drugs
under “Fast Track designation” as a “priority review” when no adequate therapy
exists. For example, FDA Approved Bevyxxa, the first and only anticoagulant for
hospital and extended duration prophylaxis of venous thromboembolism (VTE) in
adult patients hospitalized for an acute medical illness who are at risk for
thromboembolic complications due to moderate or severe restricted mobility and
other risk factors for VTE. Approximately 24 million acutely ill medical
patients are hospitalized each year and are at risk of VTE, either while in the
hospital or following discharge. The speedy approval by FDA drives the growth
of anti-thrombotic drugs market. In May 2019, FDA approved Fragmin (dalteparin
sodium) injection, for subcutaneous use, to reduce the recurrence of
symptomatic venous thromboembolism (VTE) in pediatric patients of one month age
and older. Hence, these approvals would as well encourage the drug
manufacturers to spend on Research & Development but would also act as a
driver.
In the year 2018, Sanofi acquired
Bioverativ for $11.6 Billion. The acquisition helped Sanofi to mark its
presence in in rare blood disorder and specialty care. Bioverative Inc. is
headquartered in Walthan, United States and was established in the year 2016.
Major players in the market are Bayer
AG, Johnson & Johnson, Sanofi, Boehringer Ingelheim Gmbh and Eli Lilly.
FOR MORE DETAILS :-
https://www.wiseguyreports.com/reports/4588871-anti-thrombotics-global-market-report-2020-including-1
About Us:
Wise Guy Reports is part of the Wise Guy Research
Consultants Pvt. Ltd. and offers premium progressive statistical surveying,
market research reports, analysis & forecast data for industries and governments
around the globe.
Contact Us:
NORAH
TRENT
Ph: +162-825-80070
(US)
Ph: +44 2035002763 (UK)
Comments
Post a Comment